Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy in other blood and solid cancers, these therapies have yielded limited success in clinical trials for both newly diagnosed and recurrent GBM. A deeper understanding of GBM’s resistance to immunotherapy is essential for enhancing treatment responses and translating results seen in other cancer models. Objectives: In this review, we examine clinical trial outcomes involving ICIs and CAR-T for GBM patients and explore the evasive mechanisms of GBM and the tumor microenvironment. Findings and Discussion: Multiple clinical trials investigating ICIs in GBM have shown poor outcomes, with no significant improvement in progression-free survival (PFS) or overall survival (OS). Results from smaller case studies with CAR-T therapy have warranted further investigation. However, no large-scale trials or robust studies have yet established these immunotherapeutic approaches as definitive treatment strategies. Future research should shift focus from addressing the scarcity of functional T cells to exploiting the abundant myeloid-derived cells within the tumor microenvironment. Conclusions: Translating these therapies into effective treatments for glioblastoma in humans remains a significant challenge. The highly immunosuppressive nature of GBM and its tumor microenvironment continue to hinder the success of these innovative immunotherapeutic approaches. Targeting the myeloid-derived compartment may lead to more robust and sustained immune responses.
Background: Glioblastoma (GBM) remains the most aggressive primary brain tumor with limited treatment options. The immunosuppressive tumor microenvironment (TME), largely shaped by tumor-associated macrophages (TAMs), represents a significant barrier to effective immunotherapy. Objective: This review aims to explore the role of TAMs within the TME, highlighting the phenotypic plasticity, interactions with tumor cells, and potential therapeutic targets to enhance anti-tumor immunity. Findings: TAMs constitute a substantial portion of the TME, displaying functional plasticity between immunosuppressive and pro-inflammatory phenotypes. Strategies targeting TAMs include depletion, reprogramming, and inhibition of pro-tumor signaling pathways. Preclinical studies show that modifying TAM behavior can shift the TME towards a pro-inflammatory state, enhancing antitumor immune responses. Clinical trials investigating inhibitors of TAM recruitment, polarization, and downstream signaling pathways reveal promising yet limited results, necessitating further research to optimize approaches. Conclusions: Therapeutic strategics targeting TAM plasticity through selective depletion, phenotypic reprogramming, or modulation of downstream immunosuppressive signals represent promising avenues to overcome GBM-associated immunosuppression. Early clinical trials underscore their safety and feasibility, yet achieving meaningful clinical efficacy requires deeper mechanistic understanding and combinatorial approaches integrating macrophage-direct therapies with existing immunotherapeutic modalities.
Tumor-treating fields (TTF) have been shown to slow glioblastoma (GBM) cell growth through mitotic arrest, increased membrane and blood-brain barrier permeability, and other cellular mechanisms. TTF as currently used prolongs GBM survival by 5 months, but there are areas of possible improvement. One of the interesting problems is optimization of TTF delivery to tumor cells, which is attenuated by intervening anatomy and shunting. Current research involving invasive approaches including cranial remodeling, intracortical TTF and intratumoral modulation therapy (IMT) may improve outcomes. Present the history of TTF and discuss current areas of research with a focus on invasive TTF. We obtained and analyzed studies referencing TTF, invasive TTF, and any of transcranial electrical stimulation (tES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), peripheral nervous system (PNS), focused ultrasound (FUS), and transcranial magnetic stimulation (TMS) with respect to mechanism of action or anti-cancer-related effects. Invasive strategies including cranial remodeling and IMT, through stereotaxis like DBS, would help alleviate the current limitations of TTF. In addition, FUS and VNS induce similar blood brain barrier effects and immune modulation as TTF that may enhance and promote an insurmountable host immune response against the immunosuppressive tumor microenvironment. TTF as currently practiced is a remarkable advance in cancer treatment. Improvements which exploit the effects of TTF in combination with other neuromodulatory modalities or in immunotherapy promise to improve this even further.
28 April 2025 in Journal of Neurosurgery: Case Lessons
BACKGROUND: Spinal intradural hematoma (SIH) is a rare condition with potential for permanent neurological deficit. SIH can be managed conservatively with serial imaging or surgically with lumbar drainage or open evacuation. We present 3 SIH cases managed with multiple surgical techniques, including a novel lumbar drainage-and-advancement technique, and review the literature. OBSERVATIONS: Patient 1 was a 35-year-old peripartum female with cauda equina syndrome after epidural analgesia. MRI revealed SIH at L4–5, necessitating urgent L3–S1 laminectomy and hematoma evacuation. Patient 2 was a 47-year-old male with bilateral lower extremity radiculopathy following posterior decompression and fusion for an L5 compression fracture. MRI revealed SIH extending from T3–L5. Focal decompression and lumbar drain placement with cranial advancement were performed for complete evacuation. Patient 3 was a 75-year-old male with urinary retention after restarting anticoagulation 4 days postlaminectomy for resection of a large synovial cyst at L4–5. MRI demonstrated a subdural collection suggestive of hygroma. A focal laminectomy with intrathecal decompression and a lumbar drain were used to completely evacuate the lesion. LESSONS: SIH management should be individualized. Focal decompression is effective for localized hematomas, while extensive, multilevel SIH may benefit from a lumbar drain with controlled cranial advancement, irrigation, and decompression. https://thejns.org/doi/10.3171/CASE25108
6 July 2026 in Journal of Neurosurgery: Case Lessons
BACKGROUND: Acute disseminated encephalomyelitis (ADEM) is a rare immune-mediated condition associated with a range of neurological sequelae, including dystonia. Deep brain stimulation (DBS) has been established as an effective therapy for various forms of primary and secondary dystonia; however, its use in dystonia secondary to ADEM remains scarcely reported. Here, the authors present a case of dystonia following an episode of ADEM in childhood unresponsive to bilateral DBS of the globus pallidus internus (GPi). OBSERVATIONS: The authors report the case of a 12-year-old patient presenting with medication-refractory generalized dystonia secondary to infantile ADEM. Following onset of ADEM at 22 months of age, the patient began exhibiting motor skill regression and progressive generalized dystonia. The dystonia remained refractory to numerous medications, including anticonvulsant, dopaminergic, anticholinergic, and muscle relaxant agents. The decision was made to perform bilateral GPi DBS. The Burke-Fahn-Marsden Dystonia Rating Scale–Motor was used to assess treatment outcomes before and after surgery. At 12 months postoperation, no significant improvements or adverse effects were observed. LESSONS: Age of onset and duration of dystonic symptoms must be considered when evaluating pediatric patients for DBS treatment of dystonia secondary to ADEM. https://thejns.org/doi/10.3171/CASE25979
14 April 2025 in Journal of Neurosurgery: Case Lessons
BACKGROUND: Dermoid cysts are benign ectodermal growths that commonly form at cranial sutures. Although benign, resection is often recommended to prevent intracranial extension as the cyst grows. The prognosis after resection is very good, provided a complete resection is possible. OBSERVATIONS: The authors present the case of a 10-month-old male patient with an occipital scalp dermoid cyst with intracranial extension who underwent subtotal resection and later presented with cerebellar extension. LESSONS: Scalp dermoid cysts with intradiploic extension have a significant risk of intracranial extension. Thus, care must be taken to achieve total resection in the first attempt or provide close follow-up before intracranial extension develops. https://thejns.org/doi/10.3171/CASE2548